| HOME >> MEDICINE >> TECHNOLOGY |
(5,177)$
(187)$
(10,002)$
(391)Other income/(expense)Other income/(expense)111(193)141(214)Change in fair value of contingent consideration related to acquisition(8,600)—(8,600)—Total other income/(expense)(8,489)(193)(8,459)(214)Net loss(13,666)(380)(18,461)(605)Basic and diluted net loss per share(0.24)(0.01)(0.33)(0.01)Shares used in computing basic and diluted net loss per share56,21748,32556,06248,160Non-GAAP Reconciliation –Net Loss to Adjusted Net Loss and Adjusted Net Loss per Share:Net loss$
(13,666)$
(380)$
(18,461)$
(605)Fair value adjustment to the liability for contingent payments to the former Nellix shareholders (non-cash)8,600—8,600—Adjusted net loss$
(5,066)$
(380)$
(9,861)$
(605)Adjusted net loss per share$
(0.09)$
(0.01)$
(0.18)$
(0.01)ENDOLOGIX, INC.CONDENSED CONSOLIDATED BALANCE SHEETSUnaudited(In thousands)June 30,December 31,20112010ASSETSCurrent assets:Cash and cash equivalents$
30,865$
38,191Accounts receivable, net12,56012,212Other receivables379515Inventories13,5688,350Other current assets846560Total current assets58,21859,828Property and equipment, net2,6682,429Goodwill27,07327,073Intangibles, net44,15144,863Other assets187182Total Assets$
132,297$
134,375LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable and accrued expenses$
13,525$
11,243Current liabilities13,52511,243Long term liabilities:Other long term liabilities1,0461,029Contingently issuable common stock36,80028,200Long term liabilities37,84629,229Total liabilities51,37140,472Stockholders' equity:Common stock, $.001 par value; 75,000 shares authorized, and 57,760 and 56,896 shares issued, and 57,265 and 56,401 outstanding5857Additional paid-in capital235,500230,01
'/>"/>
| SOURCE Endologix, Inc. Copyright©2010 PR Newswire. All rights reserved |